Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A Richards for Oncology Nurses

Featuring an interview with Dr Tiffany A Richards, including the following topics: Current treatment landscape for multiple myeloma (MM) (0:00) CAR (chimeric antigen receptor) T-cell therapy for the management of MM (10:22) Bispecific antibodies for relapsed/refractory MM (24:26) Case: A woman in her early 80s with relapsed MM receives teclistamab (35:56) Case: A man in his early 70s with multiregimen-refractory MM receives linvoseltamab on a clinical trial (44:06) Case: A woman in her early 60s with relapsed MM and extramedullary disease receives talquetamab (48:38) Role of nurses in transitions of care for patients with MM (53:15) Case: A man in his mid 70s with heavily pretreated MM experiences a response to teclistamab (58:56) Risk of second cancers with bispecific antibodies and other immunotherapy-based treatment approaches (1:00:55) NCPD information and select publications